Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux

Completed · Phase 1 · Has a placebo group

Conditions studied: Laryngopharyngeal Reflux

In brief

The purpose of this study is to determine whether treatment with twice-daily Lansoprazole 30mg (Prevacid 30mg) and behavioral modifications for reflux is superior to treatment with behavioral modifications for reflux alone in the treatment of laryngopharyngeal reflux (LPR).

Key facts

Study ID

NCT00864396

Run by

University of California, Davis

People needed

59

Starts

2005-07-01

Expected to finish

2008-05-01

Last updated by the study team

2017-03-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients with a clinical diagnosis of laryngopharyngeal reflux diagnosed by any combination of patient symptoms, physical/endoscopic findings, and 24 hr dual-probe ambulatory pH-testing.
• 18 years of age or older

You may not qualify if…

• patients with life-threatening complications of laryngeal, pharyngeal or esophageal cancer, subglottic or tracheal stenosis, laryngeal papilloma, airway compromise
• elite vocal performs with LPR-related dysphonia
• under 18 years of age
• pregnant and/or lactating women
• persons with known hypersensitivity to any component of the formulation
• patients taking theophylline, ketoconazole, ampicillin or digoxin
• persons with hepatic and renal insufficiency

Where it is running

• University of California Davis Medical Center — Sacramento, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.